CA2945770A1 - Powder coating compositions for coating pharmaceutical pellets - Google Patents
Powder coating compositions for coating pharmaceutical pellets Download PDFInfo
- Publication number
- CA2945770A1 CA2945770A1 CA2945770A CA2945770A CA2945770A1 CA 2945770 A1 CA2945770 A1 CA 2945770A1 CA 2945770 A CA2945770 A CA 2945770A CA 2945770 A CA2945770 A CA 2945770A CA 2945770 A1 CA2945770 A1 CA 2945770A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- composition according
- coating
- glycol
- polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008188 pellet Substances 0.000 title claims abstract description 85
- 239000000843 powder Substances 0.000 title claims abstract description 72
- 239000008199 coating composition Substances 0.000 title claims abstract description 20
- 238000000576 coating method Methods 0.000 title claims description 102
- 239000011248 coating agent Substances 0.000 title claims description 87
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 239000004014 plasticizer Substances 0.000 claims abstract description 58
- 229920000642 polymer Polymers 0.000 claims abstract description 52
- 239000007788 liquid Substances 0.000 claims abstract description 27
- 239000002216 antistatic agent Substances 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 230000002708 enhancing effect Effects 0.000 claims abstract description 17
- 230000009477 glass transition Effects 0.000 claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 229920001577 copolymer Polymers 0.000 claims description 20
- -1 glycol ethers Chemical class 0.000 claims description 20
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 14
- 238000013265 extended release Methods 0.000 claims description 14
- 239000000454 talc Substances 0.000 claims description 14
- 235000012222 talc Nutrition 0.000 claims description 14
- 229910052623 talc Inorganic materials 0.000 claims description 14
- 229940033134 talc Drugs 0.000 claims description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 12
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims description 12
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims description 12
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 12
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 12
- 230000003111 delayed effect Effects 0.000 claims description 11
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 230000000873 masking effect Effects 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 9
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 235000013772 propylene glycol Nutrition 0.000 claims description 9
- 235000002639 sodium chloride Nutrition 0.000 claims description 9
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920002301 cellulose acetate Polymers 0.000 claims description 7
- 230000001079 digestive effect Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 239000001087 glyceryl triacetate Substances 0.000 claims description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000058 polyacrylate Polymers 0.000 claims description 6
- 229920001451 polypropylene glycol Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229960002622 triacetin Drugs 0.000 claims description 6
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 5
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 5
- 229920000193 polymethacrylate Polymers 0.000 claims description 5
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 claims description 3
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 claims description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 3
- ZFEKANLLFQEKED-UHFFFAOYSA-N 2-propan-2-yloxypropan-1-ol Chemical compound CC(C)OC(C)CO ZFEKANLLFQEKED-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 3
- 229920003153 Eudragit® NE polymer Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 claims description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 3
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 239000006229 carbon black Substances 0.000 claims description 3
- 235000019241 carbon black Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 229920003086 cellulose ether Polymers 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 229940099371 diacetylated monoglycerides Drugs 0.000 claims description 3
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940116333 ethyl lactate Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 3
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 3
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 239000004300 potassium benzoate Substances 0.000 claims description 3
- 235000010235 potassium benzoate Nutrition 0.000 claims description 3
- 229940103091 potassium benzoate Drugs 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 235000011008 sodium phosphates Nutrition 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 3
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 125000005591 trimellitate group Chemical group 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920003143 Eudragit® FS 30 D Polymers 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 19
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 16
- 229960002702 piroxicam Drugs 0.000 description 16
- 239000002245 particle Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 238000005507 spraying Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000005054 agglomeration Methods 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 9
- 239000007888 film coating Substances 0.000 description 8
- 238000009501 film coating Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000013022 formulation composition Substances 0.000 description 7
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 229920001688 coating polymer Polymers 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229910002024 Aerosil® 200 Pharma Inorganic materials 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229920003118 cationic copolymer Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012232 pharmaceutical film coating Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure provides powder coating compositions for pharmaceutical pellets which include one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95 % w/w. The compositions include one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100°C. The compositions also include one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25 % w/w. The compositions may also include one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95 % w/w.
Description
POWDER COATING COMPOSITIONS FOR COATING PHARMACEUTICAL
PELLETS
FIELD
The present disclosure relates to powder coating compositions for coating pharmaceutical pellets.
BACKGROUND
Orally administered pharmaceutical products such as tablets are typically coated for many different reasons, including anyone or combination of moisture protection, delayed release of the medicinally active component, targeted drug delivery, extended release, taste masking, taste modification, and aesthetic appeal, to mention a few reasons.
Tablets have been coated using pan coaters in which the tablet cores to the coating are typically sprayed in either powder or liquid form, or a combination of =
both. Electrostatic powder coating is a relatively new film coating technique for the manufacture of coated tablets to achieve a wide range of functions such as modified release, moisture protection, aesthetics and taste masking functions.
It is an environmental friendly and cost effective method that can potentially replace the existing aqueous and solvent coating methods. Electrostatic powder coating using a pan coating apparatus was introduced in United States Patent Publication No.
2007/0128274.
In addition to tablets, another orally administered pharmaceutical product is made of pellets which are much smaller than tablets. These smaller pellets can be orally administered in pre-set dosage amounts such as pellets in filled hard gelatin capsules, or they can be compressed together with additional excipients to form larger tablets such that these tablets are made from the smaller pellets.
Typically, the administration of oral pellets provide significant clinical benefits such as consistent bioavailability of modified release products and patient safety benefits compared to monolithic tablets such as reduction of dose dumping of extended released formulations. It would be very advantageous to be able to coat these individual pellets but for the coated pellets to be viable the resulting coating must be uniform and coating the entire pellet surface.
The inventors have noted that the same formulations used for powder coating of tablets alone are not adequate for multi-particulate (pellet) coating. Due to the increased surface area and reduced bulk density of the much smaller pellets compared to the larger tablets, the agglomeration tendency of pellets is increased during the coating process. The larger specific area associated with the smaller pellets provides a more favorable environment for pellets to adhere together and their lower bulk density prevents the agglomerated pellets from separating from each other, thereby resulting in unevenly coated pellets.
One of the reasons for agglomeration during coating is due to polymer film stickiness associated with the polymers used to form the coatings. For example, coating of oral pharmaceutical products is commonly conducted using a liquid coating process where a coating film is produced by concurrent deposition and drying of polymeric coating material. The film coat is generally non-sticky when it is not wet and the product temperature is not too high. However, since the glass
PELLETS
FIELD
The present disclosure relates to powder coating compositions for coating pharmaceutical pellets.
BACKGROUND
Orally administered pharmaceutical products such as tablets are typically coated for many different reasons, including anyone or combination of moisture protection, delayed release of the medicinally active component, targeted drug delivery, extended release, taste masking, taste modification, and aesthetic appeal, to mention a few reasons.
Tablets have been coated using pan coaters in which the tablet cores to the coating are typically sprayed in either powder or liquid form, or a combination of =
both. Electrostatic powder coating is a relatively new film coating technique for the manufacture of coated tablets to achieve a wide range of functions such as modified release, moisture protection, aesthetics and taste masking functions.
It is an environmental friendly and cost effective method that can potentially replace the existing aqueous and solvent coating methods. Electrostatic powder coating using a pan coating apparatus was introduced in United States Patent Publication No.
2007/0128274.
In addition to tablets, another orally administered pharmaceutical product is made of pellets which are much smaller than tablets. These smaller pellets can be orally administered in pre-set dosage amounts such as pellets in filled hard gelatin capsules, or they can be compressed together with additional excipients to form larger tablets such that these tablets are made from the smaller pellets.
Typically, the administration of oral pellets provide significant clinical benefits such as consistent bioavailability of modified release products and patient safety benefits compared to monolithic tablets such as reduction of dose dumping of extended released formulations. It would be very advantageous to be able to coat these individual pellets but for the coated pellets to be viable the resulting coating must be uniform and coating the entire pellet surface.
The inventors have noted that the same formulations used for powder coating of tablets alone are not adequate for multi-particulate (pellet) coating. Due to the increased surface area and reduced bulk density of the much smaller pellets compared to the larger tablets, the agglomeration tendency of pellets is increased during the coating process. The larger specific area associated with the smaller pellets provides a more favorable environment for pellets to adhere together and their lower bulk density prevents the agglomerated pellets from separating from each other, thereby resulting in unevenly coated pellets.
One of the reasons for agglomeration during coating is due to polymer film stickiness associated with the polymers used to form the coatings. For example, coating of oral pharmaceutical products is commonly conducted using a liquid coating process where a coating film is produced by concurrent deposition and drying of polymeric coating material. The film coat is generally non-sticky when it is not wet and the product temperature is not too high. However, since the glass
2 transition temperature of the coating material is lowered in the presence of plasticiser(s) and solvent, the coat surface can become sticky if the solvent is not evaporated quickly or the coating temperature is too high relative to the glass transition temperature. This results in product agglomeration if the product is over wetted due to insufficient product movement in the coating pan and/or excessive spray rate of coating material and high coating temperature. In powder coating, the glass transition temperature of the coating material is also decreased to facilitate film forming. An excessive reduction of the glass transition temperature increases the tackiness of the film coating causing agglomeration. The agglomeration is
3.13 particularly problematic for pellets versus tablets as the pellets have a much smaller inertia to break off from each other.
Another reason of agglomeration of solid oral products in coating is the presence of electrostatic charge. Electrostatic charged surfaces attract much stronger than non-charged surfaces because of the stronger electrostatic force of charged units than the non-specific van der Waal force of the non-charged units.
This is particularly problematic for the much smaller pellets than it is for the much larger tablets since much lighter pellets when charged up can electrostatically bind to oppositely charged pellets which results in stronger bonding than associated with lower surface area to volume tablets.
As noted above, agglomeration must be avoided to produce a quality film in coating of pellets. Agglomeration causes coating surface defects, coating dissolution failure, and in-vivo performance issues. Agglomeration of tablets and pellets in pharmaceutical film coating is a common cause of product manufacturing failures and inter- and intra-batch-to-batch variations in product performance such as bioavailability and absorption characteristics.
Therefore, the formulations used for powder coating of small pellets must include not only the functional constituents which give the resulting coat with desired pharmaceutical properties, but also must include constituents which facilitate the production of uniform coatings on the pellets during the powder coating process.
Thus, it would be very advantageous to provide formulations for electrostatic spray powder coating of pellets which avoid the aforementioned limitations.
SUMMARY
The present disclosure provides powder coating compositions for pharmaceutical pellets which include one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95 % w/w. The compositions include one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100 C. The compositions also include one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25 % w/w.
The one or more film forming polymers may be present in the composition in a range from about 10 to about 70 % w/w.
Another reason of agglomeration of solid oral products in coating is the presence of electrostatic charge. Electrostatic charged surfaces attract much stronger than non-charged surfaces because of the stronger electrostatic force of charged units than the non-specific van der Waal force of the non-charged units.
This is particularly problematic for the much smaller pellets than it is for the much larger tablets since much lighter pellets when charged up can electrostatically bind to oppositely charged pellets which results in stronger bonding than associated with lower surface area to volume tablets.
As noted above, agglomeration must be avoided to produce a quality film in coating of pellets. Agglomeration causes coating surface defects, coating dissolution failure, and in-vivo performance issues. Agglomeration of tablets and pellets in pharmaceutical film coating is a common cause of product manufacturing failures and inter- and intra-batch-to-batch variations in product performance such as bioavailability and absorption characteristics.
Therefore, the formulations used for powder coating of small pellets must include not only the functional constituents which give the resulting coat with desired pharmaceutical properties, but also must include constituents which facilitate the production of uniform coatings on the pellets during the powder coating process.
Thus, it would be very advantageous to provide formulations for electrostatic spray powder coating of pellets which avoid the aforementioned limitations.
SUMMARY
The present disclosure provides powder coating compositions for pharmaceutical pellets which include one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95 % w/w. The compositions include one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100 C. The compositions also include one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25 % w/w.
The one or more film forming polymers may be present in the composition in a range from about 10 to about 70 % w/w.
4 The one or more flow enhancing agents may be present in the composition in a range from about 0.25 to about 20 % w/w.
The one or more flow enhancing agents may be present in the composition in a range from about 0.5 to about 3 % w/w.
The composition may further include one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95 % w/w.
The one or more anti-static agents may be present in the composition in a range from about 1 to about 50 % w/w.
The one or more plasticizers may include any one or combination of glycerol, propylene glycol, PEG 200 to 8000 grades, triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributyl citrate (TBC), triethyl citrate(TEC), leyl alcohol, castor oil, fractionated coconut oil, acetylated monoglycerides, glycerol monostearate. Plasticizers may also include low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene glycol) and citrate ester-type plasticizers.
The one or more plasticizers may include any one or combination of ethylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl
The one or more flow enhancing agents may be present in the composition in a range from about 0.5 to about 3 % w/w.
The composition may further include one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95 % w/w.
The one or more anti-static agents may be present in the composition in a range from about 1 to about 50 % w/w.
The one or more plasticizers may include any one or combination of glycerol, propylene glycol, PEG 200 to 8000 grades, triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributyl citrate (TBC), triethyl citrate(TEC), leyl alcohol, castor oil, fractionated coconut oil, acetylated monoglycerides, glycerol monostearate. Plasticizers may also include low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene glycol) and citrate ester-type plasticizers.
The one or more plasticizers may include any one or combination of ethylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl
5 ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutyl sebacate, acetyltributylcitrate, acetyl triethyl citrate and allyl glycolate.
The one or more anti-static agents may include common salts, carbon black, magnesium stearate, fumed silicate, magnesium trisilicate, glycerol monostearate, Kaolin, talc and a liquid plasticizer. The liquid plasticizer may include any one or combination of PEG 200 to 600, propylene glycol, glycerin, and triacetin. The common salts may include any one or combination of sodium chloride, calcium chloride, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, sodium acetate, potassium acetate, potassium citrate, potassium chloride, and magnesium sulfate.
The plasticizer may be selected to lower the glass transition temperature of the coating composition to a temperature in a range from about 45 to 70 C.
The one or more flow enhancing agents may include any one or combination of calcium stearate, colloidal silicon dioxide, hydrogenate castor oil and microcrystalline cellulose, funnaric acid, glycerol behanate, glycerol monostearate, glycerol palmitostearate, leucine, magnesium stearate, medium chain triglyceride, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil and zinc stearate.
The one or more film forming polymers may be selected to exhibit any one or combination of a moisture barrier, immediate release, flavoring, taste modifying, and taste masking, and wherein the film forming polymer includes any one or combination of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose
The one or more anti-static agents may include common salts, carbon black, magnesium stearate, fumed silicate, magnesium trisilicate, glycerol monostearate, Kaolin, talc and a liquid plasticizer. The liquid plasticizer may include any one or combination of PEG 200 to 600, propylene glycol, glycerin, and triacetin. The common salts may include any one or combination of sodium chloride, calcium chloride, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, sodium acetate, potassium acetate, potassium citrate, potassium chloride, and magnesium sulfate.
The plasticizer may be selected to lower the glass transition temperature of the coating composition to a temperature in a range from about 45 to 70 C.
The one or more flow enhancing agents may include any one or combination of calcium stearate, colloidal silicon dioxide, hydrogenate castor oil and microcrystalline cellulose, funnaric acid, glycerol behanate, glycerol monostearate, glycerol palmitostearate, leucine, magnesium stearate, medium chain triglyceride, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil and zinc stearate.
The one or more film forming polymers may be selected to exhibit any one or combination of a moisture barrier, immediate release, flavoring, taste modifying, and taste masking, and wherein the film forming polymer includes any one or combination of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose
6 (HPC), hydroxylpropyl methyl cellulose (HPMC), polyethylene glycol, propylene glycol, polaxamer and povidone, polyvinyl alcohol based composition such as Opadry AMB, Aminoalkyl methacrylate copolymers.
The one or more film forming polymers may be selected to exhibit extended release and includes any one or combination of cellulose ether derivative, acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters, ethyl =
cellulose, and poly(meth)acrylate polymers that are not soluble in digestive fluids.
The one or more film forming polymers may be selected to exhibit extended release and includes any one or combination of polyethylene oxide (PEO), ethylene oxide- propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, alginic acid and its derivatives, starch and starch derivatives, gelatin that are soluble in digestive fluids.
The poly(meth)acrylate polymers that are not soluble in digestive fluids may include any one or combination of Eudragit RS polymers, Eudragit RL
polymers, and EUDRAGIT NE polymers.
The one or more film forming polymers may be selected to exhibit delayed release include any one or combination of cellulose acetate phthalate, cellulose acetate trimaletate, hydroxyl propyl methylcellulose phthalate, polyvinyl acetate
The one or more film forming polymers may be selected to exhibit extended release and includes any one or combination of cellulose ether derivative, acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters, ethyl =
cellulose, and poly(meth)acrylate polymers that are not soluble in digestive fluids.
The one or more film forming polymers may be selected to exhibit extended release and includes any one or combination of polyethylene oxide (PEO), ethylene oxide- propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, alginic acid and its derivatives, starch and starch derivatives, gelatin that are soluble in digestive fluids.
The poly(meth)acrylate polymers that are not soluble in digestive fluids may include any one or combination of Eudragit RS polymers, Eudragit RL
polymers, and EUDRAGIT NE polymers.
The one or more film forming polymers may be selected to exhibit delayed release include any one or combination of cellulose acetate phthalate, cellulose acetate trimaletate, hydroxyl propyl methylcellulose phthalate, polyvinyl acetate
7 phthalate, acrylic polymers, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, methacrylic copolymers with carboxylic acid groups.
The methacrylic copolymers with carboxylic acid groups may include Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit SI00, Acryl-EZE .
A further understanding of the functional and advantageous aspects of the present disclosure can be realized by reference to the following detailed description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Embodiments disclosed herein will be more fully understood from the following detailed description thereof taken in connection with the accompanying drawings, which form a part of this application, and in which:
Figure 1 is an example dissolution profile of coated pellets with taste-masking film forming polymer powder;
Figure 2 is an example dissolution profile of coated pellets with extended-release film forming polymer powder; and Figure 3 is an example dissolution profile of coated pellets with delayed film forming polymer powder.
DETAILED DESCRIPTION
Various embodiments and aspects of the disclosure will be described with reference to details discussed below. The following description and drawings are
The methacrylic copolymers with carboxylic acid groups may include Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit SI00, Acryl-EZE .
A further understanding of the functional and advantageous aspects of the present disclosure can be realized by reference to the following detailed description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Embodiments disclosed herein will be more fully understood from the following detailed description thereof taken in connection with the accompanying drawings, which form a part of this application, and in which:
Figure 1 is an example dissolution profile of coated pellets with taste-masking film forming polymer powder;
Figure 2 is an example dissolution profile of coated pellets with extended-release film forming polymer powder; and Figure 3 is an example dissolution profile of coated pellets with delayed film forming polymer powder.
DETAILED DESCRIPTION
Various embodiments and aspects of the disclosure will be described with reference to details discussed below. The following description and drawings are
8 illustrative of the disclosure and are not to be construed as limiting the disclosure.
Numerous specific details are described to provide a thorough understanding of various embodiments of the present disclosure. However, in certain instances, well-known or conventional details are not described in order to provide a concise discussion of embodiments of the present disclosure.
As used herein, the terms, "comprises" and "comprising" are to be construed as being inclusive and open ended, and not exclusive. Specifically, when used in the specification and claims, the terms, "comprises" and "comprising"
and variations thereof' mean the specified features, steps or components are included. These terms are not to be interpreted to exclude the presence of other features, steps or components.
As used herein, the term "exemplary" means "serving as an example, instance, or illustration," and should not be construed as preferred or advantageous over other configurations disclosed herein.
As used herein, the terms "about" and "approximately" are meant to cover variations that may exist in the upper and lower limits of the ranges of values, such as variations in properties, parameters, and dimensions. In one non-limiting example, the terms "about" and "approximately" mean plus or minus 10 percent or less.
As used herein the phrases pellets, beads and spheroids (hereinafter pellets) are interchangeable terms as used herein to refer to small spherical or close to spherical single particles or agglomerations of fine powders or granules of pharmaceutical ingredients. It will be noted pellets may not be spherical but could
Numerous specific details are described to provide a thorough understanding of various embodiments of the present disclosure. However, in certain instances, well-known or conventional details are not described in order to provide a concise discussion of embodiments of the present disclosure.
As used herein, the terms, "comprises" and "comprising" are to be construed as being inclusive and open ended, and not exclusive. Specifically, when used in the specification and claims, the terms, "comprises" and "comprising"
and variations thereof' mean the specified features, steps or components are included. These terms are not to be interpreted to exclude the presence of other features, steps or components.
As used herein, the term "exemplary" means "serving as an example, instance, or illustration," and should not be construed as preferred or advantageous over other configurations disclosed herein.
As used herein, the terms "about" and "approximately" are meant to cover variations that may exist in the upper and lower limits of the ranges of values, such as variations in properties, parameters, and dimensions. In one non-limiting example, the terms "about" and "approximately" mean plus or minus 10 percent or less.
As used herein the phrases pellets, beads and spheroids (hereinafter pellets) are interchangeable terms as used herein to refer to small spherical or close to spherical single particles or agglomerations of fine powders or granules of pharmaceutical ingredients. It will be noted pellets may not be spherical but could
9 have other shapes, such as but not limited to cylindrical, cubical etc.
Pellets can be coated or uncoated, depending on its end usage. The pellet size ranges for commercially available pharmaceutical uncoated pellets is typically in the range from about 100 to about 2000 pm (0.10 to 2.00 mm). As used herein, pellets have sizes in a range from about 50 to about 3,000 pm (microns) (0.30 to 3.00 mm), with a preferable size range being from about 100 to about 2,000 pm. Uncoated pellets are prepared using a variety of palletisation methods including, but not limited to, wet granulation, extrusion/spheronization, hot melt extrusion, fluidbed layering, or powder layering methods.
Defined quantities of coated or uncoated pellets are filled into capsules or compressed into tablets along with pharmaceutically acceptable excipients to produce a dosage unit for oral administration. Pellets can also be administered directly or dispersed in a liquid as an oral suspension for oral administration. The use of pellets is not limited to oral administration. For example, pellets can be mixed with a semisolid based composition, such as, but not limited to creams, for use as a topical product.
In contrast, pharmaceutical tablets for humans have sizes in a range from about 5 mm to about 25 mm in the longest dimension of round, oblong, oval or any other shapes.
As used herein the phrase "film forming polymers" refer to polymers that produce a physical, continuous film upon curing when used as a coating material for powder coating. The continuous film may or not may not contain a plasticizer.
Film forming polymers together with other pharmaceutical agents are used to produce functional, cosmetic or a combination thereof, film coats for pharmaceutical products. One or more film forming polymer coatings can provide one or a combination of, but not limited to, the following characteristics: 1) moisture protection, e.g. moisture protective film coating of a tablet or pellets; 2) delayed release characteristics, e.g. enteric film coating so that a drug will not be released in the stomach before it reaches the upper intestine; 3) targeted drug delivery, e.g.
a delayed pH sensitive film coating of a tablet or pellets to colonic delivery of a drug so that the drug will start releasing in the lower Cl tract; 4) extended release, e.g. a sustained release film coating of a tablet or pellets to provide prolonged drug released at a constant rate for a period of time after drug administration where product is typically taken once or twice daily instead several times a day; 5) taste masking to prevent dissolution in the mouth, and similarly taste modifying agents in the coating; and 6)10w dose coating, e.g. a small amount (low dose) of drug substance is embedded in the polymer coating of a low dose product. The present disclosure provides compositions used to improve content uniformity of low dose products.
As used herein the phrase "plasticizer" refers to additives that soften a polymer by lowering its glass transition temperature or reducing its crystallinity or melting temperature. For powder coatings, an appropriate level of a plasticizer allows the polymer/plasticizer material to coalesce to form a continuous polymeric film at a defined time and temperature. Plasticizers also refer to additives for polymers for imparting desired viscosity, flexibility, plasticity and any other physical properties to produce a suitable coating film that can withstand the mechanical =
handling forces in the film coating process, product transfer, and packaging and transportation.
As used herein the phrase "anti-static agents" refers to additives that help eliminate electrostatic charges generated on a surface of pellets or tablets.
One mechanism of charge elimination is obtained by increasing the conductivity of the surface in the presence of an electro-conducting anti-static agent. Another charge elimination mechanism is the use of a hygroscopic anti-static agent so that the surface moisture on pellet or tablet enhances charge dispersion. Anti-static agents prevent powder particle adhesion to each other and to non-electrical bonded or poorly bonded surfaces.
As used herein the phrase "flow enhancing agents" refers to additives that improve the flowability of powders. A suitable flow enhancing agent enables effective bulk powder transfer to the electrostatic spray gun during powder coating process.
The present compositions have been developed to provide compositions that exhibit the required film forming and processing characteristics for uniform and non-agglomerating film coating of pellets. The inventors have surprisingly found, that a combination of excipients with the following functional properties produce well-formed (coated) pellets using electrostatic powder coating processes.
These functional properties include film forming polymers for the intended release characteristics, plasticizers for optimal film forming temperature, anti-static agents for charge distribution, and flow aids for metering powders for coating.
One surprising finding of these powder coatings is that the powder coating formulations can be prepared in a pan coater. Because of the difficulties in coating pellets compared to tablets, the liquid coating of pellets are generally produced using a fluidbed with Wurster inserts, see United States Patent No. 3,241,520 (Wruster 1966) which shows a bottom sprayed fluidized bed with a Wurster insert.
Film Forming Polymers Film forming polymers that can achieve, immediate release, flavoring or taste modifying/masking or moisture barrier include, but are not limited to, any one or combination of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (H PC), hydroxylpropyl methyl cellulose (HPMC), polyethylene glycol, propylene glycol, polaxamer and povidone, polyvinyl alcohol based composition such as Opadry AMB, Aminoalkyl methacrylate copolymers such as Eudragit E.
Coating polymers that could achieve extended release include, but not limit to a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters or a combination of any thereof, or it can include ethyl cellulose, cellulose acetate, poly(meth)acrylates polymers that are not soluble in digestive fluids such as Eudragit RS and RL polymers with alkaline groups and EUDRAGIT NE polymers with neutral groups.
Coating polymers that exhibit extended release include water soluble polymers such as, but not limit to, polyethylene oxide (PEO), ethylene oxide-propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g.
poloxamer), carbonner, polycarbophil, chitosan, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (H PC), hydroxyethyl cellulose, hydroxymethyl cellulose and hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, polyhydroxyalkylcarboxylic acids, alginic acid and its derivatives such as carrageenate alginates, ammonium alginate and sodium alginate, starch and starch derivatives, polysaccharides, carboxypolymethylene, polyethylene glycol, natural gums such as gum guar, gum acacia, gum tragacanth, karaya gum and gum xanthan, povidone, gelatin or the like. Coating polymers that could achieve delayed release include, but are not limited to, any one or combination of cellulose acetate phthalate, cellulose acetate trimaletate, hydroxyl propyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, methacrylic copolymers with carboxylic acid groups (such as Eudragit L30D, Eudragit L100, Eudragit FS300, Eudragit SI00, Acryl-EZE ).
It will be appreciated by those skilled in the art that multiple coats may be applied to the pellets with each coat selected to have a pre-determined functionality as set out above with respect to the film forming polymers.
=
=
Plasticizers Both liquid and solid plasticizers can be used to achieve the target glass transition temperature for powder coating, and may be present in the composition in quantity to lower the glass transition temperature of the coating composition to broadly in the temperature range from about 30 to 100 C and more preferably from 45 to 70 C. It has been surprisingly found that the liquid plasticizers have multiple functions in the present pellet coatings. The functions of the plasticizers used include: 1) lowering the glass transition temperature (i.e., increase in molecular mobility) of the film forming polymer(s) to produce satisfactory functional or cosmetic coating for oral pharmaceutical formulations; 2) increased adhesion of the film forming powder to the pellet substrate; and 3) increasing the electrical conductivity on spraying the substrate surface during coating. Thus the surface plasticizer also acts as an anti-static agent before it is incorporated into coating polymer matrix to produce a polymer film.
The plasticizers can be incorporated with the chain of the main formulation of the film forming coating powder, as a result, the free volume between polymer chains can be increased and the glass transition temperature of the polymer powder can be reduced dramatically. When the plasticizer is comprised of liquid polymers or polymer solutions, a certain amount of the plasticizer on the surface of the pellets can also decrease the electrical resistance of the pellets dramatically so that the adhesion of charged coating powder and the coating uniformity and efficiency is improved. Furthermore, a certain amount of liquid plasticizer or plasticizer solution can provide a strong capillary force between particles and allow polymer sintering and film formation to occur.
Plasticizers suitable for use in the present coating formulations include, but are not limited to, glycerol, propylene glycol, PEG 200-600 grades, triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP) and tributyl citrate (TBC), triethyl citrate(TEC), castor oil, fractionated coconut oil, acetylated monoglycerides and glycerol monostearate.
Plasticizers suitable for use in the present invention also include, but are not limited to, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, and citrate ester-type plasticizers. Such plasticizers can also include ethylene glycol, 1,2- butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutyl sebacate, acetyltributylcitrate, acetyl triethyl citrate, tributyl citrate and ally' glycolate.
Anti-static agents The one or more anti-static agents may include common salts, carbon black, magnesium stearate, fumed silicate, magnesium trisilicate, glycerol monostearate, Kaolin, talc and a liquid plasticizer. The liquid plasticizer may include any one or combination of PEG 200 to 600, propylene glycol, glycerin, and triacetin. The common salts may include, but are not limited to, any one or combination of sodium chloride, calcium chloride, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, sodium acetate, potassium acetate, potassium citrate, potassium chloride, and magnesium sulfate. The anti-static agents may be present in the composition in a range from about 0.1 to about 95 % w/w, and more preferably in a range from about 1 to about 50 % w/w.
Flow enhancing agents The one or more flow enhancing agents may include any one or combination of calcium stearate, colloidal silicon dioxide, hydrogenate castor oil and microcrystalline cellulose, fumaric acid, glycerol behanate, glycerol monostearate, glycerol palmitostearate, leucine, magnesium stearate, medium chain triglyceride, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil and zinc stearate.
The one or more flow enhancing agents in powder form may be present in the composition in a range from about 0.1 to about 25 % w/w, and more preferably from about 0.25 to about 20 % w/w. In embodiments the one or more flow enhancing agents is present in the composition in a range from about 0.5 to about 3 % w/w.
Several non-limiting examples are given below.
EXAMPLES
In the present examples, piroxicam pellets were used as the model drug coating pellets to demonstrate the effectiveness of the electrostatic powder coating compositions provided in the present disclosure. Three different classes of functional pharmaceutical polymers compositions containing Eudragit EPO, Eudragit RS/RL, Acryl-EZE , were selected to achieve taste masking, extended release and delayed release, respectively.
Dry powder coating of piroxicam pellets with a taste masking coating (Eudragit EPO) This example demonstrates the dry powder coating of piroxicam pellets using a coating composition (Table 1) containing Eudragit EPO (a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), a pH sensitive polymer that is soluble in gastric juice up to pH 5.0, swellable and permeable above pH 5.0, and a liquid plasticizer, polyethylene glycol 400 (PEG 400, EMD Chemicals Inc. Ontario, Canada), is used to increase the adhesion between the coating powder and the piroxicam pellets.
Talc is used as the anti-static agent and colloidal silicon dioxide is used as the flow enhancing agent.
Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in Table 1. Eudragit EPO and colloidal silicon dioxide (AEROSIL 200 Pharma) were donated by Evonik Degussa Corporation (Germany). Talc was purchased from Mallinckrodt Baker Inc.
(Canada).
Table 1 Composition of taste masking coating powder*
Formulation Composition (% w/w) Eudragit EPO 10.0 Talc 89.0 Colloidal silicon dioxide(nano level) 0.5 Pigment(FD&C Yellow No.6) 0.5 *The plasticizer, PEG 400, is included in the coating composition by spraying onto the coating pellets. The particle size (volume mean diameter) D[4,3] of the above used Eudragit EPO and Talc powder are 13.3pm and 28.9pm, respectively.
1) Powder coating process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 40 C at a rotating speed of 20 rpm.
Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 40 C. Liquid plasticizer (PEG 400) was sprayed on to the particles from an atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds.
1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins 3 times until the target coating level was achieved. The particles were cured at 40 C and a rotating speed of 20 rpm for hours.
2) Dissolution Test The coated piroxicam pellets was visually examined in phosphate buffer solution (PBS) at pH 6.8. No dissolution was observed and the film coat was intact for up to 10 minutes. The dissolution profile of coated piroxicam pellets in 0.1 N
HCI solution (pH=1.2) was obtained using an USP dissolution apparatus (Apparatus 2) at 37 C and a rotation speed of 100 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 334 nm. The PBS and rapid dissolution in 0.1N HCI results shown in Figure 1 indicate that the coated pellets exhibit taste masking behavior, i.e. little or no dissolution upon swallowing and rapid dissolution when the product reaches the stomach.
=
Dry powder coated piroxicam pellets with extended release coating (Eudragit RS/RL) This example demonstrate the dry powder coating of piroxicam pellets using a coating composition (Table 2) containing Eudragit RS (a low permeability copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups.) and Eudragit RL(a high premeabillity copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups.), two pH independent polymers that are commonly used for extended release coating. A liquid plasticizer, triethyl citrate (TEC, Caledon Laboratories Ltd. Ontario, Canada), is also used to increase the adhesion between the coating powder and the piroxicam pellets and to decrease the Tg of the Eudragit RS/RL from 63-65 to around 35 C. Talc is used as the anti-static agent and colloidal silicon dioxide is used as the flow enhancing agent.
1) Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in 2) Formulation Composition (%w/w) =
Eudragit RS 40.0 Eudragit RL 40.0 Talc 19.0 Colloidal silicon dioxide (nano level) 0.5 Pigment( FD&C Blue number 1) 0.5 Table 2. Eudragit RS and Eudragit RL and colloidal silicon dioxide (AEROSIL 200 Pharma) were donated by Evonik Degussa Corporation (Germany). Talc was purchased from Mallinckrodt Baker Inc. (Canada).
3) Formulation Composition (`Yow/w) Eudragit RS 40.0 Eudragit RL 40.0 Talc 19.0 Colloidal silicon dioxide (nano level) 0.5 Pigment( FD&C Blue number 1) 0.5 Table 2 Composition of extended release coating powder*
*A liquid plasticizer, TEC, is included in the coating composition by spraying onto the coating pellets.
The particle size (volume mean diameter) D[4,3] of the above used Eudragit RS, Eudragit RL and Talc were 47.7pm, 40.8pm and 28.9 pm, respectively.
4) Powder Coating Process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 50 C at a rotating speed of 20 rpm.
Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 50 C. Liquid plasticizer (TEC) was sprayed on to the particles from an atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds. 1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins 6 times until the target coating level was achieved. The particles were cured at 50 C and a rotating speed of 20 rpm for hours.
5) Dissolution test The dissolution profile of coated piroxicam pellets in pH=7.0 phosphate buffer solution was obtained using an USP dissolution apparatus (Apparatus 2) at 37 C
and a rotation speed of 50 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 354 nm. Figure 2 is the dissolution profile of the coated piroxicam pellets with Eudragit RS/RL which demonstrated the expected extended release function of the coated formulation.
Dry powder coated piroxicam pellets with delayed release coating (Acryl-EZE`) This example demonstrates the dry powder coating of piroxicann pellets using a enteric coating composition (Table 3) containing Acryl-EZE (contains Eudragit L100-55, an anionic copolymer based on methacrylic acid and ethyl acrylate provided by Colorcon Inc. USA), a formulated coating pH sensitive coating powder that is soluble in water at a pH above 5.5.
A liquid plasticizer, polyethylene glycol 400 (PEG 400, EMD Chemicals Inc.
Ontario, Canada), is used to increase the adhesion between the coating powder and the piroxicann pellets and to decrease the Tg of the Acryl-EZE from 133 C
to 50-55 C. The plasticizer also serves as an anti-static agent.
1) Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in Table 3.
Table 3 Composition of delayed release coating materials*
Formulation Composition (% w/w) Acryl-EZE 99.5 pigment (FD&C Blue number 1) 0.5 *The plasticizer, PEG 400, is included in the coating composition by spraying onto the coating pellets. The particle size (volume mean diameter) D[4,3] of the above used Acryl-EZE was 20.5pm.
2) Powder coating process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 50 C at a rotating speed of 20 rpm. Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 50 C. Liquid plasticizer (PEG 400) was sprayed on to the particles from a atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds. 1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins for several times (4 times for coating level of 13.25 % w/w; 7 times for 21.93 % w/w) until the target coating level =
was achieved. The particles were cured at 50 C and a rotating speed of 20 rpm for 2 hours.
3) Dissolution test The dissolution profile of coated piroxicam pellets was obtained in 0.1 N
(pH=1.2) HCI solution for 2 hours (acid stage) and in pH=6.8 phosphate buffer solution after the acid stage using an USP dissolution apparatus at 37 C and at a rotation speed of 100 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 334 nm (acid stage samples) and 353 nm (buffer stage samples).
The delayed release profiles of the coated pellets at coating level of 13.25 and 21.93 % w/w are shown in Figure 3. In both cases, the results met and exceeded the requirements of the acid resistance test of percent release of not more than
Pellets can be coated or uncoated, depending on its end usage. The pellet size ranges for commercially available pharmaceutical uncoated pellets is typically in the range from about 100 to about 2000 pm (0.10 to 2.00 mm). As used herein, pellets have sizes in a range from about 50 to about 3,000 pm (microns) (0.30 to 3.00 mm), with a preferable size range being from about 100 to about 2,000 pm. Uncoated pellets are prepared using a variety of palletisation methods including, but not limited to, wet granulation, extrusion/spheronization, hot melt extrusion, fluidbed layering, or powder layering methods.
Defined quantities of coated or uncoated pellets are filled into capsules or compressed into tablets along with pharmaceutically acceptable excipients to produce a dosage unit for oral administration. Pellets can also be administered directly or dispersed in a liquid as an oral suspension for oral administration. The use of pellets is not limited to oral administration. For example, pellets can be mixed with a semisolid based composition, such as, but not limited to creams, for use as a topical product.
In contrast, pharmaceutical tablets for humans have sizes in a range from about 5 mm to about 25 mm in the longest dimension of round, oblong, oval or any other shapes.
As used herein the phrase "film forming polymers" refer to polymers that produce a physical, continuous film upon curing when used as a coating material for powder coating. The continuous film may or not may not contain a plasticizer.
Film forming polymers together with other pharmaceutical agents are used to produce functional, cosmetic or a combination thereof, film coats for pharmaceutical products. One or more film forming polymer coatings can provide one or a combination of, but not limited to, the following characteristics: 1) moisture protection, e.g. moisture protective film coating of a tablet or pellets; 2) delayed release characteristics, e.g. enteric film coating so that a drug will not be released in the stomach before it reaches the upper intestine; 3) targeted drug delivery, e.g.
a delayed pH sensitive film coating of a tablet or pellets to colonic delivery of a drug so that the drug will start releasing in the lower Cl tract; 4) extended release, e.g. a sustained release film coating of a tablet or pellets to provide prolonged drug released at a constant rate for a period of time after drug administration where product is typically taken once or twice daily instead several times a day; 5) taste masking to prevent dissolution in the mouth, and similarly taste modifying agents in the coating; and 6)10w dose coating, e.g. a small amount (low dose) of drug substance is embedded in the polymer coating of a low dose product. The present disclosure provides compositions used to improve content uniformity of low dose products.
As used herein the phrase "plasticizer" refers to additives that soften a polymer by lowering its glass transition temperature or reducing its crystallinity or melting temperature. For powder coatings, an appropriate level of a plasticizer allows the polymer/plasticizer material to coalesce to form a continuous polymeric film at a defined time and temperature. Plasticizers also refer to additives for polymers for imparting desired viscosity, flexibility, plasticity and any other physical properties to produce a suitable coating film that can withstand the mechanical =
handling forces in the film coating process, product transfer, and packaging and transportation.
As used herein the phrase "anti-static agents" refers to additives that help eliminate electrostatic charges generated on a surface of pellets or tablets.
One mechanism of charge elimination is obtained by increasing the conductivity of the surface in the presence of an electro-conducting anti-static agent. Another charge elimination mechanism is the use of a hygroscopic anti-static agent so that the surface moisture on pellet or tablet enhances charge dispersion. Anti-static agents prevent powder particle adhesion to each other and to non-electrical bonded or poorly bonded surfaces.
As used herein the phrase "flow enhancing agents" refers to additives that improve the flowability of powders. A suitable flow enhancing agent enables effective bulk powder transfer to the electrostatic spray gun during powder coating process.
The present compositions have been developed to provide compositions that exhibit the required film forming and processing characteristics for uniform and non-agglomerating film coating of pellets. The inventors have surprisingly found, that a combination of excipients with the following functional properties produce well-formed (coated) pellets using electrostatic powder coating processes.
These functional properties include film forming polymers for the intended release characteristics, plasticizers for optimal film forming temperature, anti-static agents for charge distribution, and flow aids for metering powders for coating.
One surprising finding of these powder coatings is that the powder coating formulations can be prepared in a pan coater. Because of the difficulties in coating pellets compared to tablets, the liquid coating of pellets are generally produced using a fluidbed with Wurster inserts, see United States Patent No. 3,241,520 (Wruster 1966) which shows a bottom sprayed fluidized bed with a Wurster insert.
Film Forming Polymers Film forming polymers that can achieve, immediate release, flavoring or taste modifying/masking or moisture barrier include, but are not limited to, any one or combination of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (H PC), hydroxylpropyl methyl cellulose (HPMC), polyethylene glycol, propylene glycol, polaxamer and povidone, polyvinyl alcohol based composition such as Opadry AMB, Aminoalkyl methacrylate copolymers such as Eudragit E.
Coating polymers that could achieve extended release include, but not limit to a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters or a combination of any thereof, or it can include ethyl cellulose, cellulose acetate, poly(meth)acrylates polymers that are not soluble in digestive fluids such as Eudragit RS and RL polymers with alkaline groups and EUDRAGIT NE polymers with neutral groups.
Coating polymers that exhibit extended release include water soluble polymers such as, but not limit to, polyethylene oxide (PEO), ethylene oxide-propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g.
poloxamer), carbonner, polycarbophil, chitosan, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (H PC), hydroxyethyl cellulose, hydroxymethyl cellulose and hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, polyhydroxyalkylcarboxylic acids, alginic acid and its derivatives such as carrageenate alginates, ammonium alginate and sodium alginate, starch and starch derivatives, polysaccharides, carboxypolymethylene, polyethylene glycol, natural gums such as gum guar, gum acacia, gum tragacanth, karaya gum and gum xanthan, povidone, gelatin or the like. Coating polymers that could achieve delayed release include, but are not limited to, any one or combination of cellulose acetate phthalate, cellulose acetate trimaletate, hydroxyl propyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, methacrylic copolymers with carboxylic acid groups (such as Eudragit L30D, Eudragit L100, Eudragit FS300, Eudragit SI00, Acryl-EZE ).
It will be appreciated by those skilled in the art that multiple coats may be applied to the pellets with each coat selected to have a pre-determined functionality as set out above with respect to the film forming polymers.
=
=
Plasticizers Both liquid and solid plasticizers can be used to achieve the target glass transition temperature for powder coating, and may be present in the composition in quantity to lower the glass transition temperature of the coating composition to broadly in the temperature range from about 30 to 100 C and more preferably from 45 to 70 C. It has been surprisingly found that the liquid plasticizers have multiple functions in the present pellet coatings. The functions of the plasticizers used include: 1) lowering the glass transition temperature (i.e., increase in molecular mobility) of the film forming polymer(s) to produce satisfactory functional or cosmetic coating for oral pharmaceutical formulations; 2) increased adhesion of the film forming powder to the pellet substrate; and 3) increasing the electrical conductivity on spraying the substrate surface during coating. Thus the surface plasticizer also acts as an anti-static agent before it is incorporated into coating polymer matrix to produce a polymer film.
The plasticizers can be incorporated with the chain of the main formulation of the film forming coating powder, as a result, the free volume between polymer chains can be increased and the glass transition temperature of the polymer powder can be reduced dramatically. When the plasticizer is comprised of liquid polymers or polymer solutions, a certain amount of the plasticizer on the surface of the pellets can also decrease the electrical resistance of the pellets dramatically so that the adhesion of charged coating powder and the coating uniformity and efficiency is improved. Furthermore, a certain amount of liquid plasticizer or plasticizer solution can provide a strong capillary force between particles and allow polymer sintering and film formation to occur.
Plasticizers suitable for use in the present coating formulations include, but are not limited to, glycerol, propylene glycol, PEG 200-600 grades, triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP) and tributyl citrate (TBC), triethyl citrate(TEC), castor oil, fractionated coconut oil, acetylated monoglycerides and glycerol monostearate.
Plasticizers suitable for use in the present invention also include, but are not limited to, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, and citrate ester-type plasticizers. Such plasticizers can also include ethylene glycol, 1,2- butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutyl sebacate, acetyltributylcitrate, acetyl triethyl citrate, tributyl citrate and ally' glycolate.
Anti-static agents The one or more anti-static agents may include common salts, carbon black, magnesium stearate, fumed silicate, magnesium trisilicate, glycerol monostearate, Kaolin, talc and a liquid plasticizer. The liquid plasticizer may include any one or combination of PEG 200 to 600, propylene glycol, glycerin, and triacetin. The common salts may include, but are not limited to, any one or combination of sodium chloride, calcium chloride, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, sodium acetate, potassium acetate, potassium citrate, potassium chloride, and magnesium sulfate. The anti-static agents may be present in the composition in a range from about 0.1 to about 95 % w/w, and more preferably in a range from about 1 to about 50 % w/w.
Flow enhancing agents The one or more flow enhancing agents may include any one or combination of calcium stearate, colloidal silicon dioxide, hydrogenate castor oil and microcrystalline cellulose, fumaric acid, glycerol behanate, glycerol monostearate, glycerol palmitostearate, leucine, magnesium stearate, medium chain triglyceride, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil and zinc stearate.
The one or more flow enhancing agents in powder form may be present in the composition in a range from about 0.1 to about 25 % w/w, and more preferably from about 0.25 to about 20 % w/w. In embodiments the one or more flow enhancing agents is present in the composition in a range from about 0.5 to about 3 % w/w.
Several non-limiting examples are given below.
EXAMPLES
In the present examples, piroxicam pellets were used as the model drug coating pellets to demonstrate the effectiveness of the electrostatic powder coating compositions provided in the present disclosure. Three different classes of functional pharmaceutical polymers compositions containing Eudragit EPO, Eudragit RS/RL, Acryl-EZE , were selected to achieve taste masking, extended release and delayed release, respectively.
Dry powder coating of piroxicam pellets with a taste masking coating (Eudragit EPO) This example demonstrates the dry powder coating of piroxicam pellets using a coating composition (Table 1) containing Eudragit EPO (a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), a pH sensitive polymer that is soluble in gastric juice up to pH 5.0, swellable and permeable above pH 5.0, and a liquid plasticizer, polyethylene glycol 400 (PEG 400, EMD Chemicals Inc. Ontario, Canada), is used to increase the adhesion between the coating powder and the piroxicam pellets.
Talc is used as the anti-static agent and colloidal silicon dioxide is used as the flow enhancing agent.
Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in Table 1. Eudragit EPO and colloidal silicon dioxide (AEROSIL 200 Pharma) were donated by Evonik Degussa Corporation (Germany). Talc was purchased from Mallinckrodt Baker Inc.
(Canada).
Table 1 Composition of taste masking coating powder*
Formulation Composition (% w/w) Eudragit EPO 10.0 Talc 89.0 Colloidal silicon dioxide(nano level) 0.5 Pigment(FD&C Yellow No.6) 0.5 *The plasticizer, PEG 400, is included in the coating composition by spraying onto the coating pellets. The particle size (volume mean diameter) D[4,3] of the above used Eudragit EPO and Talc powder are 13.3pm and 28.9pm, respectively.
1) Powder coating process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 40 C at a rotating speed of 20 rpm.
Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 40 C. Liquid plasticizer (PEG 400) was sprayed on to the particles from an atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds.
1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins 3 times until the target coating level was achieved. The particles were cured at 40 C and a rotating speed of 20 rpm for hours.
2) Dissolution Test The coated piroxicam pellets was visually examined in phosphate buffer solution (PBS) at pH 6.8. No dissolution was observed and the film coat was intact for up to 10 minutes. The dissolution profile of coated piroxicam pellets in 0.1 N
HCI solution (pH=1.2) was obtained using an USP dissolution apparatus (Apparatus 2) at 37 C and a rotation speed of 100 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 334 nm. The PBS and rapid dissolution in 0.1N HCI results shown in Figure 1 indicate that the coated pellets exhibit taste masking behavior, i.e. little or no dissolution upon swallowing and rapid dissolution when the product reaches the stomach.
=
Dry powder coated piroxicam pellets with extended release coating (Eudragit RS/RL) This example demonstrate the dry powder coating of piroxicam pellets using a coating composition (Table 2) containing Eudragit RS (a low permeability copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups.) and Eudragit RL(a high premeabillity copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups.), two pH independent polymers that are commonly used for extended release coating. A liquid plasticizer, triethyl citrate (TEC, Caledon Laboratories Ltd. Ontario, Canada), is also used to increase the adhesion between the coating powder and the piroxicam pellets and to decrease the Tg of the Eudragit RS/RL from 63-65 to around 35 C. Talc is used as the anti-static agent and colloidal silicon dioxide is used as the flow enhancing agent.
1) Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in 2) Formulation Composition (%w/w) =
Eudragit RS 40.0 Eudragit RL 40.0 Talc 19.0 Colloidal silicon dioxide (nano level) 0.5 Pigment( FD&C Blue number 1) 0.5 Table 2. Eudragit RS and Eudragit RL and colloidal silicon dioxide (AEROSIL 200 Pharma) were donated by Evonik Degussa Corporation (Germany). Talc was purchased from Mallinckrodt Baker Inc. (Canada).
3) Formulation Composition (`Yow/w) Eudragit RS 40.0 Eudragit RL 40.0 Talc 19.0 Colloidal silicon dioxide (nano level) 0.5 Pigment( FD&C Blue number 1) 0.5 Table 2 Composition of extended release coating powder*
*A liquid plasticizer, TEC, is included in the coating composition by spraying onto the coating pellets.
The particle size (volume mean diameter) D[4,3] of the above used Eudragit RS, Eudragit RL and Talc were 47.7pm, 40.8pm and 28.9 pm, respectively.
4) Powder Coating Process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 50 C at a rotating speed of 20 rpm.
Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 50 C. Liquid plasticizer (TEC) was sprayed on to the particles from an atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds. 1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins 6 times until the target coating level was achieved. The particles were cured at 50 C and a rotating speed of 20 rpm for hours.
5) Dissolution test The dissolution profile of coated piroxicam pellets in pH=7.0 phosphate buffer solution was obtained using an USP dissolution apparatus (Apparatus 2) at 37 C
and a rotation speed of 50 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 354 nm. Figure 2 is the dissolution profile of the coated piroxicam pellets with Eudragit RS/RL which demonstrated the expected extended release function of the coated formulation.
Dry powder coated piroxicam pellets with delayed release coating (Acryl-EZE`) This example demonstrates the dry powder coating of piroxicann pellets using a enteric coating composition (Table 3) containing Acryl-EZE (contains Eudragit L100-55, an anionic copolymer based on methacrylic acid and ethyl acrylate provided by Colorcon Inc. USA), a formulated coating pH sensitive coating powder that is soluble in water at a pH above 5.5.
A liquid plasticizer, polyethylene glycol 400 (PEG 400, EMD Chemicals Inc.
Ontario, Canada), is used to increase the adhesion between the coating powder and the piroxicann pellets and to decrease the Tg of the Acryl-EZE from 133 C
to 50-55 C. The plasticizer also serves as an anti-static agent.
1) Preparation Of The Coating Powder The coating powder was prepared using a blade grind mill for about 25 seconds following the composition shown in Table 3.
Table 3 Composition of delayed release coating materials*
Formulation Composition (% w/w) Acryl-EZE 99.5 pigment (FD&C Blue number 1) 0.5 *The plasticizer, PEG 400, is included in the coating composition by spraying onto the coating pellets. The particle size (volume mean diameter) D[4,3] of the above used Acryl-EZE was 20.5pm.
2) Powder coating process 40 g piroxicam pellets were loaded into the rotatable drum of a rotary powder coating apparatus and was pre-heated to 50 C at a rotating speed of 20 rpm. Then the rotation speed of the drum was increased to 70 rpm and the temperature was maintained at 50 C. Liquid plasticizer (PEG 400) was sprayed on to the particles from a atomizing spraying nozzle at a flow rate of 0.25 g/min for 35 seconds. 1.5 g coating materials were immediately deposited to the coating particles after plasticizer spraying. The plasticizer spraying and coating materials deposition cycle was repeated after about 15 mins for several times (4 times for coating level of 13.25 % w/w; 7 times for 21.93 % w/w) until the target coating level =
was achieved. The particles were cured at 50 C and a rotating speed of 20 rpm for 2 hours.
3) Dissolution test The dissolution profile of coated piroxicam pellets was obtained in 0.1 N
(pH=1.2) HCI solution for 2 hours (acid stage) and in pH=6.8 phosphate buffer solution after the acid stage using an USP dissolution apparatus at 37 C and at a rotation speed of 100 rpm. The dissolution samples were assayed using a UV-Vis spectrophotometer at a wavelength of 334 nm (acid stage samples) and 353 nm (buffer stage samples).
The delayed release profiles of the coated pellets at coating level of 13.25 and 21.93 % w/w are shown in Figure 3. In both cases, the results met and exceeded the requirements of the acid resistance test of percent release of not more than
10% released in 0.1 N HCI in 2 hours.
All of the formulation compositions can be made and executed without undue experimentation in light of the present disclosure. While the formulation compositions, methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the formulation compositions, and/or apparatus and/or methods and in the steps or in the sequence of steps of the methods described herein.
More specifically, it will be apparent that certain agents that are chemically or physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art.
All of the formulation compositions can be made and executed without undue experimentation in light of the present disclosure. While the formulation compositions, methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the formulation compositions, and/or apparatus and/or methods and in the steps or in the sequence of steps of the methods described herein.
More specifically, it will be apparent that certain agents that are chemically or physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art.
Claims (20)
1. A powder coating composition for pharmaceutical pellets, comprising:
a) one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95 % w/w;
b) one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100°C; and c) one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25 % w/w.
a) one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95 % w/w;
b) one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100°C; and c) one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25 % w/w.
2. The composition according to claim 1, wherein the one or more film forming polymers is present in the composition in a range from about 10 to about 70 %
w/w.
w/w.
3. The composition according to claim 1, wherein the one or more flow enhancing agents is present in the composition in a range from about 0.25 to about 20 % w/w.
4. The composition according to claim 1, wherein the one or more flow enhancing agents is present in the composition in a range from about 0.5 to about 3.0 % w/w.
5. The composition according to any one of claims 1 to 4, wherein the one or more plasticizers include any one or combination of glycerol, propylene glycol, PEG 200 to 8000 grades, triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributyl citrate (TBC), triethyl citrate(TEC), castor oil, fractionated coconut oil, acetylated monoglycerides, glycerol monostearate, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene glycol) and citrate ester-type plasticizers,
6. The composition according to any one of claims 1 to 4, wherein the one or more plasticizers include any one or combination of ethylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, monopropylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutyl sebacate, acetyltributylcitrate, acetyl triethyl citrate and allyl glycolate.
7. The composition according to any one of claims 1 to 6, further comprising one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95 % w/w.
8. The composition according to 7, wherein the one or more anti-static agents are present in the composition in a range from about 1 to about 50 % w/w.
9. The composition according to claim 7 or 8, wherein the one or more anti-static agents include common salts, carbon black, magnesium stearate, fumed silicate, magnesium trisilicate, glycerol monostearate, Kaolin, talc and a liquid plasticizer.
10. The composition according to claim 9, wherein said liquid plasticizer includes any one or combination of PEG 200 to 600, propylene glycol, glycerin, and triacetin.
11. The composition according to claim 9, wherein said common salts includes any one or combination of sodium chloride, calcium chloride, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, sodium acetate, potassium acetate, potassium citrate, potassium chloride, and magnesium sulfate
12. The composition according to claim 1, wherein said plasticizer is selected to lower the glass transition temperature of the coating composition to a temperature in a range from about 45 to 70°C.
13. The composition according to any one of claims 1 to 12, wherein the one or more flow enhancing agents include any one or combination of calcium stearate, colloidal silicon dioxide, hydrogenate castor oil and microcrystalline cellulose, fumaric acid, glycerol behanate, glycerol monostearate, glycerol palmitostearate, leucine, magnesium stearate, medium chain triglyceride, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil and zinc stearate.
14. The composition according to any one of claims 1 to 13, wherein the one or more film forming polymers is selected to exhibit any one or combination of a moisture barrier, immediate release, flavoring, taste modifying, and taste masking, and wherein the film forming polymer includes any one or combination of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (HPC), hydroxylpropyl methyl cellulose (HPMC), polyethylene glycol, propylene glycol, polaxamer and povidone, polyvinyl alcohol based composition such as Opadry®
AMB, Aminoalkyl methacrylate copolymers.
AMB, Aminoalkyl methacrylate copolymers.
15. The composition according to any one of claims 1 to 13, wherein the one or more film forming polymers is selected to exhibit extended release and includes any one or combination of cellulose ether derivative, acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters, ethyl cellulose, and poly(meth)acrylate polymers that are not soluble in digestive fluids.
16. The composition according to any one of claims 15 wherein the poly(meth)acrylate polymers that are not soluble in digestive fluids include any one or combination of Eudragit® RS polymers, Eudragit® RL polymers, and EUDRAGIT® NE
polymers.
polymers.
17. The composition according to any one of claims 1 to 13, wherein the one or more film forming polymers is selected to exhibit extended release and includes any one or combination of polyethylene oxide (PEO), ethylene oxide- propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, alginic acid and its derivatives, starch and starch derivatives, gelatin that are soluble in digestive fluids.
18. The composition according to any one of claims 1 to 13, wherein the one or more film forming polymers is selected to exhibit delayed release include any one or combination of cellulose acetate phthalate, cellulose acetate trimaletate, hydroxyl propyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, methacrylic copolymers with carboxylic acid groups.
19. The composition according to claim 18 wherein the methacrylic copolymers with carboxylic acid groups include Eudragit® L30D, Eudragit® L100, Eudragit®
FS30D, Eudragit® SI00, Acryl-EZE®.
FS30D, Eudragit® SI00, Acryl-EZE®.
20. The composition according to any one of claims 1 to 19 applied multiple times to the pellets with each different coating selected to have a pre-determined functionality.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2945770A CA2945770A1 (en) | 2016-10-19 | 2016-10-19 | Powder coating compositions for coating pharmaceutical pellets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2945770A CA2945770A1 (en) | 2016-10-19 | 2016-10-19 | Powder coating compositions for coating pharmaceutical pellets |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2945770A1 true CA2945770A1 (en) | 2018-04-19 |
Family
ID=61968913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2945770A Abandoned CA2945770A1 (en) | 2016-10-19 | 2016-10-19 | Powder coating compositions for coating pharmaceutical pellets |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2945770A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110063943A (en) * | 2019-04-24 | 2019-07-30 | 浙江工业大学 | A kind of dry powder coating material for coating electrostatic |
CN113069496A (en) * | 2021-03-18 | 2021-07-06 | 济川药业集团有限公司 | Traditional Chinese medicine granule composition for treating infantile common cold and preparation method thereof |
-
2016
- 2016-10-19 CA CA2945770A patent/CA2945770A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110063943A (en) * | 2019-04-24 | 2019-07-30 | 浙江工业大学 | A kind of dry powder coating material for coating electrostatic |
CN110063943B (en) * | 2019-04-24 | 2021-07-27 | 浙江工业大学 | Dry powder coating material for electrostatic coating |
CN113069496A (en) * | 2021-03-18 | 2021-07-06 | 济川药业集团有限公司 | Traditional Chinese medicine granule composition for treating infantile common cold and preparation method thereof |
CN113069496B (en) * | 2021-03-18 | 2022-09-06 | 济川药业集团有限公司 | Traditional Chinese medicine granule composition for treating infantile common cold and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210186885A1 (en) | Powder coating compositions for coating pharmaceutical pellets | |
JP5502254B2 (en) | Multiparticulate dosage form consisting of at least two different coated pellet forms | |
KR101571198B1 (en) | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients | |
CA2942083C (en) | Manufacture of multiple minicapsules | |
EP0827398B1 (en) | Pharmaceutical dosage form for colonic delivery | |
JP2021503463A (en) | How to make coated hard capsules | |
JP4999037B2 (en) | Pharmaceutical dosage form with multiple coatings | |
Felton et al. | Physical and enteric properties of soft gelatin capsules coated with eudragit® L 30 D-55 | |
JPH11315017A (en) | Binder for dosage form for oral administration of solid or aqueous dispersion suitable for producing coating film, use of the aqueous dispersion and redispersible powder | |
Pan et al. | Novel compaction techniques with pellet-containing granules | |
US20190389785A1 (en) | Controlled release nutrients by coating | |
Singh et al. | Mucoadhesive pellets for drug delivery applications: a critical review | |
CA2945770A1 (en) | Powder coating compositions for coating pharmaceutical pellets | |
JP3471977B2 (en) | Enteric preparations coated with solvent-free enteric coatings using liquid plasticizers | |
CA2946952C (en) | Modified release coated capsules | |
Patel et al. | A review on enteric coated pellets composed of core pellets prepared by extrusion-spheronization | |
US20220000788A1 (en) | Method for dry powder coating capsules | |
KR100771426B1 (en) | Pharmaceutical composition using the micro-pellet and the preparation thereof | |
JP3628401B2 (en) | Enteric preparation with solvent-free enteric coating | |
JPH08333238A (en) | Enteric coated preparation coated by solventless enteric coating agent using liquid wax | |
CA2271560C (en) | Pharmaceutical dosage form for colonic delivery | |
Tirpude et al. | Drug multiparticulate production and coating technology–a review | |
CA3108257A1 (en) | Pellets having a multi-layer structure for delayed release of the active substance in the distal colon | |
CZ27703U1 (en) | Capsule containing Tamsulosin HCl in protrected release pellets | |
WO2010138064A1 (en) | Aqueous film coating composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20211013 |
|
EEER | Examination request |
Effective date: 20211013 |
|
EEER | Examination request |
Effective date: 20211013 |
|
EEER | Examination request |
Effective date: 20211013 |
|
FZDE | Discontinued |
Effective date: 20240308 |